SR33805 (oxalate)

SR33805 oxalate is a potent Ca²⁺ channel antagonist, with EC₅₀s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 oxalate blocks L-type but not T-type Ca²⁺ channels. SR33805 oxalate can be used for the research of acute or chronic failing hearts^[1][2]. In Vitro:SR33805 (0.01-10 µM; 3 d) oxalate inhibits growth factor-induced proliferation of SMC (0.2050<0.46 µM) in a dose-dependent manner^[3].
SR33805 (10 µM; 10 min) oxalate restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca²⁺ transient amplitude^[2].
SR33805 (10 µM) oxalate decreases the activity of recombinant PKA^[2]. In Vivo:SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats^[2].
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs^[3].